Heron Therapeutics earnings were -$28.0M for the trailing 12 months ending Sep 30, 2024, with N/A growth year over year. The latest HRTX earnings report on Sep 30, 2024 announced Q3 2024 earnings of -$4.8M, down 47.5% from last quarter. For the last reported fiscal year 2023 ending Dec 31, 2023, HRTX reported annual earnings of -$110.6M, with -39.3% growth.
What were Heron Therapeutics's earnings last quarter?
On HRTX's earnings call on Invalid Date, Heron Therapeutics (NASDAQ: HRTX) reported Q3 2024 earnings per share (EPS) of -$0.03, up 82.35% year over year. Total HRTX earnings for the quarter were -$4.85 million. In the same quarter last year, Heron Therapeutics's earnings per share (EPS) was -$0.17.
As of the last Heron Therapeutics earnings report, Heron Therapeutics is currently losing money. Heron Therapeutics's net profit (also called net income) for the twelve months ending Sep 30, 2024 was -$27.97 million, a 76.64% decrease year over year.
What was HRTX's earnings growth in the past year?
As of Heron Therapeutics's earnings date in Invalid Date, Heron Therapeutics's earnings has grown year over year. HRTX earnings in the past year totalled -$27.97 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.